E is a bulky substituent, but is not the side chain of D-tryptophan, L-N-methyltryptophan, L-homophenylalanine, L-2-naphthyl L-etrahydroisoquinoline, L-cyclohexylalanine, D-leucine, L-fluorenylalanine, or L-histidine;

F is the side chain of L-arginine, L-homoarginine, L-citrulline, or L-canavanine, or a bioisostere thereof; and

AFT 34 ANDT

٠5

25

X is  $-(CH_2)_nNH-$  or  $(CH_2)_n-S-$ , where n is an integer of from 1 to 4;  $-(CH_2)_2O-$ ;  $-(CH_2)_3O-$ ;  $-(CH_2)_3-$ ;  $-(CH_2)_4-$ ;  $-CH_2COCHRNH-$ ; or  $-CH_2-CHCOCHRNH-$ , where R is the side chain of any common or uncommon amino acid.

- 2. A method according to claim 1, in which n is 2 or 3.
- 15 3. A method according to claim 1 or claim 2, in which A is an acetamide group, an aminomethyl group, or a substituted or unsubstituted sulphonamide group.
  - 4. A method according to claim 2, in which A is a substituted sulphonamide, and the substituent is an alkyl
- chain of 1 to 6 carbon atoms, or a phenyl or toluyl group.
  A method according to claim 4, in which the substituent is an alkyl chain of 1 to 4 carbon atoms.
  - 6. A method according to any one of claims 1 to 5, in which B is the side chain of L-phenylalanine or L-phenylglycine.
  - 7. A method according to any one of claims 1 to 6, in which C is the side chain of glycine, alanine, leucine, valine, proline, hydroxyproline, or thioproline.
- 8. A method according to any one of claims 1 to 7,
  in which D is the side chain of D-Leucine, D-homoleucine,
  D-cyclohexylalanine, D-homocyclohexylalanine, D-valine, Dnorleucine, D-homo-norleucine, D-phenylalanine, Dtetrahydroisoquinoline, D-glutamine, D-glutamate, or Dtyrosine.
- 35 9. A method according to any one of claims 1 to 8, in which E is the side chain of an amino acid selected from the group consisting of L-phenylalanine, L-tryptophan

and L-homotryptophan, or is L-1-napthyl or L-3-benzothienyl alanine.

5

- 10. A method according to any one of claims 1 to 9, in which the inhibitor is a compound which has antagonist activity against C5aR, and has no C5a agonist activity.
- 11. A method according to any one of claims 1 to 10, in which the inhibitor has potent antagonist activity at sub-micromolar concentrations.
- 12. A method according to any one of claims 1 to 11, in which the compound has a receptor affinity IC50< 25 $\mu$ M, and an antagonist potency IC50<1 $\mu$ M.
  - 13. A method according to any one of claims 1 to 12, in which the compound is selected from the group consisting of compounds 1 to 6, 10 to 15, 17, 19, 20, 22,
- 15 25, 26, 28, 30, 31, 33 to 37, 39 to 45, 47 to 50, 52 to 58 and 60 to 70 described in PCT/AU02/01427.
  - 14. A method according to claim 13, in which the compound is PMX53 (compound 1), compound 33, compound 60 or compound 45 described in PCT/AU02/01427.
- 20 15. A method according to any one of claims 1 to 14, in which the inhibitor is used in conjunction with one or more other agents for the treatment of inflammatory bowel disease.
- 16. A method according to claim 15, in which the 25 other agent is infliximab or is an inhibitor of C3a.
  - 17. A method according to any one of claims 1 to 16, in which the treatment is to prevent or alleviate acute recurrences of inflammatory bowel disease.
  - 18. A method according to any one of claims 1 to 16,
- 30 in which the treatment is to prevent or alleviate a primary occurrence of inflammatory bowel disease.
  - 19. A method according to any one of claims 1 to 18, in which the inflammatory bowel disease is selected from the group consisting of ulcerative colitis, Crohn's
- disease, lymphocytic-plasmocytic enteritis, coeliac disease, collagenous colitis, lymphocytic colitis and eosinophilic enterocolitis, indeterminate colitis,

infectious colitis, pseudomembranous colitis (necrotizing colitis), and ischemic inflammatory bowel disease.

- 20. A method according to any one of claims 1 to 18, in which the inflammatory bowel disease is ulcerative colitis.
- 21. A method according to any one of claims 1 to 18, in which the inflammatory bowel disease is Crohn's disease.
- 22. A method according to any one of claims 1 to 18, in which the inflammatory bowel disease is selected from the group consisting of enterocolitis, canine plasmacytic-lymphocytic colitis, protothecal colitis, and histocytic ulcerative colitis.
- 23. A method according to any one of claims 1 to 20,15 in which the inhibitor is administered in an enteric coated capsule or per-rectally.
  - 24. Use of a compound as defined in any one of claims 1 to 14 in the manufacture of a medicament for the treatment of inflammatory bowel disease.

Amended Sheet IPEA/AU